Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (NASDAQ:PHVS)
· seekingalpha.com
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release. Find out why PHVS stock is a buy.
The basis for my bullish Pharvaris ( PHVS ) thesis goes beyond the potential approval of an oral treatment for acute hereditary angioedema (HAE) attacks. The mo...